Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 5, Pages 625-632
Publisher
Informa UK Limited
Online
2017-04-08
DOI
10.1080/13543784.2017.1312338
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells
- (2017) Mara Compagno et al. NATURE
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Cancer treatment and survivorship statistics, 2016
- (2016) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
- (2016) William J. Scott et al. ChemMedChem
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer
- (2016) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma
- (2016) Qingshan Yang et al. CLINICAL CANCER RESEARCH
- Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
- (2016) V M Patel et al. LEUKEMIA
- Erratum: The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells
- (2016) R Thijssen et al. LEUKEMIA
- Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate
- (2016) Catherine A. Evans et al. ACS Medicinal Chemistry Letters
- BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
- (2016) Maria-Carmela Speranza et al. Scientific Reports
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
- (2015) J. R. Brown et al. CLINICAL CANCER RESEARCH
- Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
- (2015) Q. Yang et al. CLINICAL CANCER RESEARCH
- FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
- (2015) B. W. Miller et al. CLINICAL CANCER RESEARCH
- Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer
- (2015) Elena Geuna et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
- (2015) Ursula Matulonis et al. GYNECOLOGIC ONCOLOGY
- Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers
- (2015) Bernard Barlaam et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer
- (2015) Johan F. Vansteenkiste et al. Journal of Thoracic Oncology
- The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
- (2015) K Balakrishnan et al. LEUKEMIA
- Take (STAT)5: jazzing up T-cell leukemia
- (2014) P. Porcu et al. BLOOD
- IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells
- (2014) S. Dong et al. BLOOD
- A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib
- (2014) N. Elster et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
- (2014) Yuichi Ando et al. CANCER SCIENCE
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease
- (2014) Timothy D. Cushing et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer
- (2014) Benjamin Levy et al. Journal of Thoracic Oncology
- Inhibition of PI3K Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
- (2014) U. Hancox et al. MOLECULAR CANCER THERAPEUTICS
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
- (2013) D W Bowles et al. BRITISH JOURNAL OF CANCER
- PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
- (2013) David G. Winkler et al. CHEMISTRY & BIOLOGY
- PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
- (2013) B. Weigelt et al. CLINICAL CANCER RESEARCH
- Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts
- (2013) Ryan P. P. Shugg et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An educational infusion: more synergy between Blood and the American Society of Hematology
- (2012) C. E. Dunbar BLOOD
- The B-cell receptor signaling pathway as a therapeutic target in CLL
- (2012) J. A. Woyach et al. BLOOD
- Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking
- (2011) Paul Mellor et al. BIOCHEMICAL JOURNAL
- PI3K inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma
- (2011) S. A. Meadows et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases
- (2010) Ana V. Miletic et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Effect of ZSTK474, a Novel Phosphatidylinositol 3-Kinase Inhibitor, on DNA-Dependent Protein Kinase
- (2009) Dexin Kong et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor
- (2009) Dexin Kong et al. EUROPEAN JOURNAL OF CANCER
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Phosphoinositide 3-Kinases γ and δ, Linkers of Coordinate C5a Receptor-Fcγ Receptor Activation and Immune Complex-induced Inflammation
- (2008) Stephanie Konrad et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting phosphoinositide 3-kinase—Moving towards therapy
- (2007) Romina Marone et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now